Company Description
Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States.
The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.
It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform.
The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015.
Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
| Country | United States |
| IPO Date | Sep 15, 2020 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 480 |
| CEO | Ms. Leslie L. Trigg |
Contact Details
Address: 3052 Orchard Drive San Jose, California 95134 United States | |
| Phone | 669-231-8200 |
| Website | outsetmedical.com |
Stock Details
| Ticker Symbol | OM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $27.00 |
| CIK Code | 0001484612 |
| CUSIP Number | 690145107 |
| ISIN Number | US6901451079 |
| Employer ID | 20-0514392 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Leslie L. Trigg | President, Chief Executive Officer and Chairman |
| Nabeel Ahmed | Chief Financial Officer |
| John L. Brottem | General Counsel and Secretary |
| Marc Nash | Senior Vice President of Operations and Research & Development |
| Jean-Olivier Racine | Chief Technology Officer |
| James S. Mazzola | Head of Investor Relations |
| Nicole Shannon | Director of Marketing Communications |
| Dr. Michael Aragon M.D. | Chief Medical Officer |
| Mark Gordon M.S. | Chief Regulatory and Quality Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 16, 2024 | 144 | Filing |
| May 16, 2024 | 144 | Filing |
| May 16, 2024 | 144 | Filing |
| May 16, 2024 | 144 | Filing |
| May 10, 2024 | 144 | Filing |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 8, 2024 | 8-K | Current Report |
| May 6, 2024 | 8-K | Current Report |
| Apr 11, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 11, 2024 | DEF 14A | Other definitive proxy statements |